Compass Therapeutics, Inc. (CMPX)
D
Pipeline Grade
Financial Position (from SEC Filings)
$55.7M
Cash & Equivalents
$17.3M
Quarterly Burn Rate
10 mo
Est. Cash Runway
$420M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2027-05-01 | Phase2 Readout | — |
Active Clinical Trials (1)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06548412 | CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Bi... | PHASE2 | Recruiting | 50 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-07-01 | 8-K | Compass Therapeutics, Inc. (CMPX) (CIK 0001738021) - EXHIBIT 99.1 | EDGAR |